Detailed information for compound 508628

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 900.752 | Formula: C44H58I2N2O2
  • H donors: 2 H acceptors: 2 LogP: 9.63 Rotable bonds: 13
    Rule of 5 violations (Lipinski): 2
  • SMILES: OC(c1ccccc1)(c1ccccc1)CCC[N+]1(C)CCC(CC1)C1CC[N+](CC1)(C)CCCC(c1ccccc1)(c1ccccc1)O.[I-].[I-]
  • InChi: 1S/C44H58N2O2.2HI/c1-45(31-15-29-43(47,39-17-7-3-8-18-39)40-19-9-4-10-20-40)33-25-37(26-34-45)38-27-35-46(2,36-28-38)32-16-30-44(48,41-21-11-5-12-22-41)42-23-13-6-14-24-42;;/h3-14,17-24,37-38,47-48H,15-16,25-36H2,1-2H3;2*1H/q+2;;/p-2
  • InChiKey: DYKWWNCEKVABFK-UHFFFAOYSA-L  

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens cholinergic receptor, muscarinic 5 Starlite/ChEMBL References
Homo sapiens cholinergic receptor, muscarinic 4 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Loa Loa (eye worm) hypothetical protein 0.073 1 0.5
Mycobacterium ulcerans protease II (oligopeptidase B), PtrB 0.029 0 0.5
Trypanosoma brucei prolyl endopeptidase 0.073 1 1
Onchocerca volvulus Prolyl endopeptidase homolog 0.073 1 0.5
Mycobacterium leprae PROBABLE PROTEASE II PTRBB (OLIGOPEPTIDASE B) 0.029 0 0.5
Leishmania major prolyl oligopeptidase, putative,serine peptidase clan SC, family S9A, putative 0.073 1 1
Mycobacterium tuberculosis Probable protease II PtrBa [first part] (oligopeptidase B) 0.0653 0.8259 1
Trypanosoma cruzi prolyl endopeptidase 0.073 1 1
Schistosoma mansoni prolyl oligopeptidase (S09 family) 0.073 1 0.5
Echinococcus multilocularis prolyl endopeptidase 0.073 1 0.5
Echinococcus granulosus prolyl endopeptidase 0.073 1 0.5
Toxoplasma gondii prolyl endopeptidase 0.073 1 0.5
Schistosoma mansoni prolyl oligopeptidase (S09 family) 0.073 1 0.5

Activities

Activity type Activity value Assay description Source Reference
Activity (binding) Antagonist activity at human muscarinic M5 receptor expressed in CHO cells assessed as inhibition of basal Eu-GTP binding ChEMBL. 18395442
Activity (binding) Antagonist activity at human muscarinic M2 receptor expressed in CHO cells assessed as inhibition of basal Eu-GTP binding ChEMBL. 18395442
Activity (binding) Antagonist activity at human muscarinic M4 receptor expressed in CHO cells assessed as inhibition of basal Eu-GTP binding ChEMBL. 18395442
Activity (binding) Antagonist activity at human muscarinic M3 receptor expressed in CHO cells assessed as inhibition of basal Eu-GTP binding ChEMBL. 18395442
Activity (binding) Antagonist activity at human muscarinic M1 receptor expressed in CHO cells assessed as inhibition of basal Eu-GTP binding ChEMBL. 18395442
Activity (binding) 0 Antagonist activity at human muscarinic M5 receptor expressed in CHO cells assessed as inhibition of basal Eu-GTP binding ChEMBL. 18395442
Activity (binding) 0 Antagonist activity at human muscarinic M4 receptor expressed in CHO cells assessed as inhibition of basal Eu-GTP binding ChEMBL. 18395442
Activity (binding) 0 Antagonist activity at human muscarinic M3 receptor expressed in CHO cells assessed as inhibition of basal Eu-GTP binding ChEMBL. 18395442
Activity (binding) 0 Antagonist activity at human muscarinic M2 receptor expressed in CHO cells assessed as inhibition of basal Eu-GTP binding ChEMBL. 18395442
Activity (binding) 0 Antagonist activity at human muscarinic M1 receptor expressed in CHO cells assessed as inhibition of basal Eu-GTP binding ChEMBL. 18395442
EC50 (functional) = 67 nM Antagonist activity at human muscarinic M4 receptor expressed in CHO cells assessed as blockade of carbachol-induced inhibition of forskolin-stimulated cAMP accumulation ChEMBL. 18395442
EC50 (functional) = 67 nM Antagonist activity at human muscarinic M4 receptor expressed in CHO cells assessed as blockade of carbachol-induced inhibition of forskolin-stimulated cAMP accumulation ChEMBL. 18395442
IC50 (functional) > 1 uM Antagonist activity at human muscarinic M4 receptor expressed in CHO cells assessed as blockade of carbachol-induced inhibition of forskolin-stimulated cAMP accumulation ChEMBL. 18395442
IC50 (functional) > 1 uM Antagonist activity at human muscarinic M4 receptor expressed in CHO cells assessed as blockade of carbachol-induced inhibition of forskolin-stimulated cAMP accumulation ChEMBL. 18395442
Ki (binding) = -7.9 Displacement of [3H]N-methylscopolamine from human muscarinic M4 receptor expressed in CHO-K1 cells ChEMBL. 18395442
Ki (binding) = -6.23 Displacement of [3H]N-methylscopolamine from human muscarinic M5 receptor expressed in CHO-K1 cells ChEMBL. 18395442
Ki (binding) = 6.22 Displacement of [3H]N-methylscopolamine from human muscarinic M1 receptor expressed in CHO-K1 cells ChEMBL. 18395442
Ki (binding) = 6.43 Displacement of [3H]N-methylscopolamine from human muscarinic M3 receptor expressed in CHO-K1 cells ChEMBL. 18395442
Ki (binding) = 6.44 Displacement of [3H]N-methylscopolamine from human muscarinic M2 receptor expressed in CHO-K1 cells ChEMBL. 18395442
Log Ki (binding) = 6.22 Displacement of [3H]N-methylscopolamine from human muscarinic M1 receptor expressed in CHO-K1 cells ChEMBL. 18395442
Log Ki (binding) = 6.23 Displacement of [3H]N-methylscopolamine from human muscarinic M5 receptor expressed in CHO-K1 cells ChEMBL. 18395442
Log Ki (binding) = 6.43 Displacement of [3H]N-methylscopolamine from human muscarinic M3 receptor expressed in CHO-K1 cells ChEMBL. 18395442
Log Ki (binding) = 6.44 Displacement of [3H]N-methylscopolamine from human muscarinic M2 receptor expressed in CHO-K1 cells ChEMBL. 18395442
Log Ki (binding) = 7.9 Displacement of [3H]N-methylscopolamine from human muscarinic M4 receptor expressed in CHO-K1 cells ChEMBL. 18395442
pKb (binding) = 6.02 Antagonist activity at human muscarinic M5 receptor expressed in CHO cells assessed as inhibition of carbachol-induced Eu-GTP binding ChEMBL. 18395442
pKb (binding) = 6.04 Antagonist activity at human muscarinic M1 receptor expressed in CHO cells assessed as inhibition of carbachol-induced Eu-GTP binding ChEMBL. 18395442
pKb (binding) = 6.1 Antagonist activity at human muscarinic M2 receptor expressed in CHO cells assessed as inhibition of carbachol-induced Eu-GTP binding ChEMBL. 18395442
pKb (binding) = 6.25 Antagonist activity at human muscarinic M3 receptor expressed in CHO cells assessed as inhibition of carbachol-induced Eu-GTP binding ChEMBL. 18395442
pKb (binding) = 7.83 Antagonist activity at human muscarinic M4 receptor expressed in CHO cells assessed as inhibition of carbachol-induced Eu-GTP binding ChEMBL. 18395442
pKb (binding) = 6.02 Antagonist activity at human muscarinic M5 receptor expressed in CHO cells assessed as inhibition of carbachol-induced Eu-GTP binding ChEMBL. 18395442
pKb (binding) = 6.04 Antagonist activity at human muscarinic M1 receptor expressed in CHO cells assessed as inhibition of carbachol-induced Eu-GTP binding ChEMBL. 18395442
pKb (binding) = 6.1 Antagonist activity at human muscarinic M2 receptor expressed in CHO cells assessed as inhibition of carbachol-induced Eu-GTP binding ChEMBL. 18395442
pKb (binding) = 6.25 Antagonist activity at human muscarinic M3 receptor expressed in CHO cells assessed as inhibition of carbachol-induced Eu-GTP binding ChEMBL. 18395442
pKb (binding) = 7.83 Antagonist activity at human muscarinic M4 receptor expressed in CHO cells assessed as inhibition of carbachol-induced Eu-GTP binding ChEMBL. 18395442

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.